< Back to the Blog

About the author

Dr Mary Parman
Dr. Mary Parman is an OB/GYN with nearly 20 years of experience and a leading voice at the intersection of clinical care and women’s health technology.

Sources

  1. North American Menopause Society. (2022). The 2022 hormone therapy position statement. Menopause, 29(7), 767-794.
  2. Santoro, N., et al. (2016). Menopausal symptoms and their management. Endocrinology and Metabolism Clinics, 45(3), 641-659.
  3. Stuenkel, C.A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011.
  4. Files, J.A., et al. (2011). Bioidentical hormone therapy. Mayo Clinic Proceedings, 86(7), 673-680.
  5. Santen, R.J., et al. (2010). Postmenopausal hormone therapy: An Endocrine Society scientific statement. Journal of Clinical Endocrinology & Metabolism, 95(7 Supplement 1), s1-s66.
  6. Crandall, C.J., et al. (2023). Management of menopausal symptoms: A review. JAMA, 329(5), 405-420.
  7. Wierman, M.E., et al. (2014). Androgen therapy in women: A reappraisal. Journal of Clinical Endocrinology & Metabolism, 99(10), 3489-3510.
  8. Rossouw, J.E., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288(3), 321-333.
  9. Manson, J.E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases. JAMA, 310(13), 1353-1368.
  10. Simon, J.A., et al. (2020). Patient-reported outcomes with hormone therapy: Timing matters. Climacteric, 23(2), 123-129.

About the Oova Blog:
Our content is developed with a commitment to high editorial standards and reliability. We prioritize referencing reputable sources and sharing where our insights come from. The Oova Blog is intended for informational purposes only and is never a substitute for professional medical advice. Always consult a healthcare provider before making any health decisions.